Laura Haas

Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials

Alan F. Barker, Anne E. O’Donnell, Patrick A. Flume et al. · The Lancet Respiratory Medicine · 2014 · 210 citations

Non-cystic Fibrosis Bronchiectasis, Allergy, Placebo-controlled Phase 3 +6

Somatosensory profiles in acute herpes zoster and predictors of postherpetic neuralgia

Sybille Krämer, Petra I. Baeumler, Christian Geber et al. · Pain · 2018 · 47 citations

Inpatient costs and predictors of costs in the psychosomatic treatment of anorexia nervosa

Laura Haas, Tom Stargardt, Jonas Schreyoegg et al. · International Journal of Eating Disorders · 2011 · 26 citations

Cost-effectiveness of open versus laparoscopic appendectomy: a multilevel approach with propensity score matching

Laura Haas, Tom Stargardt, Jonas Schreyoegg · The European Journal of Health Economics · 2011 · 24 citations

Laparoscopy, Health Economics, Patient Safety +8

Two phase 3 placebo-controlled trials of aztreonam lysine for inhalation (AZLI) for non-cystic fibrosis bronchiectasis (NCFB)

Alan R. Barker, Anne O’Donnell, Philip J. Thompson et al. · 2013 · 13 citations

Interventional Pulmonology, Inflammatory Lung Disease, Advanced Lung Disease +18